Mission Statement, Vision, & Core Values (2026) of Camurus AB (publ).

Born in 1991 and headquartered in Lund, Camurus AB (Nasdaq Stockholm: CAMX) has grown into a patient-focused biopharma force operating in 12 countries with a meaningful US presence through Camurus Inc. in Princeton, New Jersey, employing over 250 people to develop long-acting injectable therapies using its proprietary FluidCrystal® technology for indications spanning opioid dependence, pain, cancer and endocrine disorders, driven by a mission to improve lives through innovative, sustainable medicines, a vision to become a global leader in long-acting treatments that reduce chronic-disease burden and expand access, and core values - Passion, Ownership, Collaboration, Quality, Innovation and Integrity - that steer partnerships with healthcare professionals and patient groups to address significant unmet needs and enhance adherence and outcomes

Camurus AB (0RD1.L) - Intro

• Founded: 1991
• Headquarters: Lund, Sweden
• Global presence: Operations in 12 countries (Europe, Australia, United States)
• Employees: >250, including a significant U.S. presence via Camurus Inc., Princeton, NJ
• Stock listing: Nasdaq Stockholm, ticker CAMX

• Mission: Develop long-acting injectable medicines that improve clinical outcomes and patient adherence for severe and chronic diseases.
• Vision: Become a leading specialty pharma company delivering durable, patient-friendly therapies worldwide through proprietary formulation technology.
• Core values:
  • Patient-centric innovation - prioritizing formulations that reduce dosing burden and enhance safety/adherence.
  • Scientific excellence - advancing FluidCrystal® and pipeline programs through rigorous R&D.
  • Collaboration & transparency - partnering with clinicians, payers and investors, and maintaining public reporting as CAMX on Nasdaq Stockholm.
  • Global impact - expanding access across markets while maintaining strong regulatory and commercial focus.

• Technology leverage: FluidCrystal® enables sustained-release profiles for injectable drug candidates, reducing dosing frequency and supporting chronic therapy adherence.
• Clinical & commercial focus: Targeting areas with high unmet need - opioid dependence and chronic pain - where long-acting formulations can materially change treatment paradigms.
• Organizational scale: A focused workforce (>250 employees) supporting R&D, regulatory, manufacturing partnerships and commercialization across 12 countries.

Camurus AB (0RD1.L) Overview

• Primary therapeutic focus: long-acting injectable and implantable formulations for chronic conditions (addiction medicine, hemophilia, endocrinology, oncology and pain management).
• Core technology: proprietary FluidCrystal® lipid-based long-acting delivery platform enabling extended-release profiles, subcutaneous depots and improved patient adherence.
• Patient-centric focus: design and development decisions guided by real-world treatment needs, patient acceptability, and quality-of-life outcomes.

• Improve lives of patients with severe and chronic diseases through innovative medical products and long-acting medicines that reduce dosing frequency and enhance adherence.
• Act with integrity and ethical behavior across R&D, clinical development, commercialization, and stakeholder engagement.
• Integrate environmental responsibility and sustainability into operations, from manufacturing practices to supply-chain choices.
• Collaborate closely with healthcare professionals and patient advocacy organizations to ensure treatments meet real-world needs and patient preferences.

• Become a leading specialty pharma company delivering best-in-class long-acting therapies globally.
• Expand the franchise of approved products (commercial launches and label extensions) while advancing a diversified pipeline into late-stage clinical development.
• Sustain profitable growth through geographic expansion, strategic partnerships, and disciplined R&D investment.

• Environmental focus: initiatives to reduce energy use and emissions in R&D and manufacturing operations; increased use of green procurement where feasible.
• Social focus: engagement with patient advocacy groups, clinician education, and access programs in relevant markets.
• Governance: emphasis on ethical conduct, compliance, and transparent stakeholder communication.

• Clinical and commercial partnerships with healthcare providers and specialty distributors to accelerate patient access and optimize treatment pathways.
• Active dialogue with patient advocacy groups to incorporate patient-reported outcomes and preferences in development and post-market activities.
• Academic collaborations and contract research partnerships to advance platform science and expand therapeutic indications.

• Growth drivers: expansion of Buvidal® sales, new indication approvals, geographic roll-outs, and progress of pipeline assets into later-stage trials.
• Investment profile: a biotech growth company profile with elevated R&D spend balanced against expanding product revenues and a healthy cash position to support development.
• Risk considerations: regulatory timing, commercialization execution, pricing and reimbursement dynamics, and clinical trial outcomes.

Camurus AB (0RD1.L) - Mission Statement

• Develop and commercialize long-acting injectable and implantable medicines based on proprietary FluidCrystal® and other delivery platforms.
• Accelerate access to life-changing therapies for patients with opioid dependence, severe endocrine disorders, and oncologic and rare disease indications.
• Maintain rigorous R&D investment to expand pipeline and create sustainable commercial growth.
• Operate with clinical, regulatory and commercial excellence to maximize global reach.

• Improve patient outcomes by providing treatments that reduce the burden of chronic conditions and improve adherence and quality of life.
• Expand global presence through regional launches and strategic partnerships to enhance access to therapies worldwide.
• Foster a culture of innovation and excellence with sustained R&D investment and talent development.
• Commit to sustainability by integrating environmental responsibility and ethical governance into operations.
• Build strong partnerships with healthcare providers, payers and communities to ensure real-world impact.

• Scale commercial operations in high-potential markets to increase uptake of long-acting therapies.
• Advance clinical pipeline through late-stage studies and regulatory submissions to broaden indications.
• Invest in platform science to extend formulation capabilities and reduce time-to-market for new assets.
• Strengthen sustainability initiatives-resource efficiency, responsible supply chain and reporting aligned with ESG frameworks.
• Deepen collaborations with healthcare systems, patient organizations and commercial partners to ensure equitable access.

Camurus AB (0RD1.L) - Vision Statement

• Passion: A relentless focus on patient impact drives project prioritization, from early discovery to market access.
• Ownership: Management and teams take responsibility for clinical, regulatory and commercial milestones to ensure delivery against strategic goals.
• Collaboration: Cross‑functional internal teams and external partners (industry, academic and commercial partners) combine capabilities to accelerate development.
• Quality: Manufacturing, regulatory compliance and pharmacovigilance standards are maintained to support sustainable global supply.
• Innovation: Platform technologies and formulation science are continuously advanced to create differentiated product candidates.
• Integrity: Ethical behavior, transparent reporting and patient safety guide all operations.

• Expand patient access to long‑acting therapies through commercial roll‑outs and partner networks.
• Invest significantly in R&D to expand pipeline indications and delivery platforms.
• Scale manufacturing capabilities with rigorous quality governance to support global launches.
• Form strategic alliances to leverage complementary capabilities and accelerate growth.

• Patient impact score - measures adherence, retention and reported outcomes for launched therapies.
• Time to regulatory milestone - average duration from phase completion to filing/approval across programs.
• Quality and compliance KPI - manufacturing batch success rate, audit findings and safety reporting timelines.
• Partner performance index - delivery against commercial milestones, revenue shares and geographic rollout speed.

• Passion & Innovation: Investment in lipid‑based and depot technologies to enable monthly or longer dosing intervals.
• Ownership & Quality: Internal manufacturing oversight and supply chain resiliency programs to minimize disruptions during scale‑up.
• Collaboration & Integrity: Transparent data sharing with regulators and partners to expedite approvals while maintaining ethical standards.